Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts.

Abstract

We studied the efficacy and pharmacokinetics of imatinib mesylate (IM) and bcr-abl expression in a Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) patient, a rare disease with a poor prognosis. Although sufficient IM trough concentrations were maintained, bcr-abl transcripts revealed only one-log reduction with IM monotherapy, suggesting a resistance against IM, and this patient required additional chemotherapy. Despite the resistance against IM at induction therapy, the patient has been in complete molecular response for more than 6 months with IM maintenance monotherapy. Our experience suggests that IM might have a positive role in consolidation and/or maintenance therapy in remission Ph + AML patients.

• Authors: Toshinori Kondo, Taizo Tasaka, Fuminori Sano, Kimiko Matsuda, Yasutaka Kubo, Yoshiko Matsuhashi, Hidekazu Nakanishi, Yoshito Sadahira, Hideho Wada, Takashi Sugihara, Kaoru Tohyama
• Journal: Leukemia research (Leuk Res) Vol. 33 Issue 9 Pg. e137-8 (Sep 2009) ISSN: 1873-5835 [Electronic] England
• PMID: 19371951 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Benzamides
• Piperazines
• Pyrimidines
• Imatinib Mesylate

Topics

• Aged
• Antineoplastic Agents (blood, pharmacokinetics, therapeutic use)
• Benzamides
• Chromatography, High Pressure Liquid
• Genes, abl
• Humans
• Imatinib Mesylate
• Leukemia, Myeloid, Acute (drug therapy, genetics)
• Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (drug therapy, genetics)
• Male
• Mass Spectrometry
• Piperazines (blood, pharmacokinetics, therapeutic use)
• Polymerase Chain Reaction
• Pyrimidines (blood, pharmacokinetics, therapeutic use)